Toxicity of radiation therapy and antiangiogenics combination: A case report;Toxicité de l'association radiothérapie et antiangiogéniques : à propos d'un cas

Cancer/Radiotherapie

Volumn 13, Issue 3, 2009, Pages 205-208

  Diaz, O ^a   Mazeron, R ^a   Martin, E ^a   Carrie, C ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

Radiotherapy; Renal cell carcinoma; Skin toxicity; Sorafenib

Indexed keywords

CORTICOSTEROID; PREDNISOLONE; SORAFENIB;

ADULT; ANAMNESIS; ARTICLE; BONE METASTASIS; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; DRUG WITHDRAWAL; HUMAN; MALE; MUSCLE METASTASIS; PRIORITY JOURNAL; RADIATION DOSE; RADIATION SICKNESS; SKIN TOXICITY; TREATMENT OUTCOME;

ADENOCARCINOMA; BENZENESULFONATES; HUMANS; KIDNEY NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUSCLE NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES; RADIODERMATITIS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 67349264860     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2009.01.002     Document Type: Article

References (11)

1. Brizel D.M., Sibley G.S., Prosnitz L.R., Scher R.L., and Dewhirst M.W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38 (1997) 285-289
2. Jain R.K. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
3. Lee C.G., Heijn M., di Tomaso E., Griffon-Etienne G., Ancukiewicz M., Koike C., et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60 (2000) 5565-5570
4. Lièvre A., Landi B., Mitry E., and Taïeb J. Antiangiogenic agents and gastrointestinal cancers. Gastroenterol Clin Biol 32 (2008) 504-520
5. Lordick F., Geinitz H., Theisen J., Sendler A., and Sarbia M. Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: Report of three cases. Int J Radiat Oncol Biol Phys 64 (2006) 1295-1298
6. Mazeron R., Bourhis J., and Deutsch E. Angiogenèse et radiothérapie : tout ce qu'un oncologue radiothérapeute doit savoir. Cancer Radiother 12 (2008) 50-60
7. Perng R.P., Chen Y.M., Ming-Liu J., Tsai C.M., Lin W.C., Yang K.Y., et al. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J Clin Oncol 15 (1997) 2097-2102
8. Peters N.A., Richel D.J., Verhoeff J.J., and Stalpers L.J. Bowel perforation after radiotherapy in a patient receiving sorafenib. J Clin Oncol 26 (2008) 2405-2406
9. Plastaras J.P., Kim S.H., Liu Y.Y., Dicker D.T., Dorsey J.F., McDonough J., et al. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 67 (2007) 9443-9454
10. ® (gemcitabine) with thoracic radiotherapy - a phase II pilot study in chemonaive patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 17 (1998) A1923
11. Zips D., Eicheler W., Geyer P., Hessel F., Dörfler A., Thames H.D., et al. Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition. Cancer Res 65 (2005) 5374-5379